Analysts Offer Insights on Healthcare Companies: Regeneron (REGN) and Baudax Bio (BXRX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Regeneron (REGNResearch Report) and Baudax Bio (BXRXResearch Report).

Regeneron (REGN)

J.P. Morgan analyst Chris Schott maintained a Hold rating on Regeneron on September 19 and set a price target of $725.00. The company’s shares closed last Tuesday at $704.22.

According to, Schott is a 1-star analyst with an average return of -1.3% and a 47.5% success rate. Schott covers the Healthcare sector, focusing on stocks such as Bausch Health Companies, Horizon Therapeutics, and Teva Pharmaceutical.

Currently, the analyst consensus on Regeneron is a Moderate Buy with an average price target of $760.67, which is a 6.9% upside from current levels. In a report issued on September 8, Jefferies also upgraded the stock to Hold with a $675.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Baudax Bio (BXRX)

In a report released today, Gregory Aurand from Noble Financial maintained a Buy rating on Baudax Bio, with a price target of $2.00. The company’s shares closed last Tuesday at $0.28, close to its 52-week low of $0.26.

According to, Aurand is ranked #7751 out of 7977 analysts.

Baudax Bio has an analyst consensus of Moderate Buy, with a price target consensus of $2.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on REGN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More